Contact us

Please use the form below to get in touch with us, or email us directly by clicking here. ∎

Disclaimer

Our content is presented for informational purposes only, and should not be construed as investment, legal, medical or health advice.

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild RideApril 18, 2025
Dr. Charles Raison has spent decades exploring how ancient practices like meditation, sauna, and psychedelics might interface with modern psychiatry. With roles spanning academia, clinical research, and biotech, he brings a rare perspective to the promises—and pitfalls—of emerging mental health treatments. Here, Psychedelic Alpha’s Josh Hardman sits down with Raison for a wide-ranging interview.
High Hopes in the Mile High City: Inside Colorado’s First Licensed Psilocybin CenterApril 17, 2025
State-regulated psychedelics are on the horizon in Colorado, as The Center Origin in Denver prepares to offer its first psilocybin session. Psychedelic Alpha spoke with Co-Founder and CEO Elizabeth Cooke about how the company became the first licensed psychedelic medicine centre in the Mile High City.
The VA, Psychedelics, and the Future of Mental Health: A Conversation with Shereef Elnahal, Former VA Under Secretary for HealthApril 14, 2025
Dr. Shereef Elnahal, former VA Under Secretary for health, discusses how he came to champion psychedelic research within the VA, the promising data in conditions like PTSD and substance use disorders, and the institutional groundwork needed to support the potential roll-out of these therapies at scale. He also shares his opinions on the balancing act between medicalisation and advocacy, and what a coordinated federal approach to psychedelics might, or should, look like.
Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability of Psilocybin’s Persistent Effects in Mice; Market Mayhem and Agency Shake-UpsApril 11, 2025
‘Everything’s On the Table’: VA Secretary Signals Openness to Psychedelics, But Concrete Plans Lacking • Drug Developers Caught Between Tariff Talk, Agency Shake-Ups, and Market Mayhem • Multi-Lab Preprint Study Challenges Replicability of Psilocybin’s Persistent Effects in Mice • Kwan Lab Links 5-HT2A Receptors and Pyramidal Tract to Psilocybin’s Lasting Effects in Mice • FDA Clears Nation’s First Whole-Mushroom Psilocybin Study • Terran vs. Compass Lawsuit Moves Forward as Court Rejects Dismissal • and more...
Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape 2025 LandscapeApril 9, 2025
As New Mexico’s Medical Psilocybin Act Passes, Questions of Access, Provider Risk, and Industry Influence Loom • Arizona’s Oregon-Style Psilocybin Services Bill Gutted and Replaced by Compass Pathways’ Crystalline Polymorph Psilocybin Rescheduling Trigger Law • A Mixed Bag for Compass’ Other Trigger Law Bills • Idaho HJR 4 Passes, Preventing Voters from Legalising Psychoactive Drugs via Ballot Initiatives • Arizona Bill Carving Out $5M for Ibogaine Research Passes House, Working Way through Senate

Contact us

Disclaimer

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights